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Identifying overexpressed genes in tumours is a critical step for tumour diagnosis, prognosis, and treatment. Using differential display
polymerase chain reaction, sequence analysis, and gene Blast searches, we discovered that human prostaglandin F synthase (hPGFS)
was upregulated in squamous cell carcinoma of the head and neck (SCCHN). Northern blot analysis indicated that up to a 16-fold
increase in the level of hPGFS expression was detected in 40.5% (15 out of 37) of SCCHN primary tumours. The increased
expression of hPGFS in SCCHN was primarily detected in SCC of larynx and hypopharynx (59%, Po0.05). Using the same primary
tissue samples, increased levels of epidermal growth factor receptor (EGFR) expression were detected in only 32% of tumour tissues,
suggesting hPGFS may have the potential to become a drug target or molecular marker for SCCHN. To determine if the increased
level of hPGFS expression came from tumour cells, we determined the level of hPGFS expression in SCCHN tumour cell lines. A high
level of hPGFS expression was detected in four out of five tumour SCCHN cell lines. To determine if upregulation of hPGFS is
SCCHN-specific, hPGFS expression was analysed in 59 tumour cell lines derived from different types of tumours. The expression of
hPGFS was increased from two- to 500-fold in a large portion of cell lines derived from lung (five out of nine), colon (five out of
seven) as well as head and neck cancer (four out of five). These data link hPGFS expression to tumours located in the respiratory and
digestive organs.
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Squamous cell carcinoma of the head and neck (SCCHN) is the
fourth most common malignancy among males in the US, with
more than 40000 cases diagnosed each year. In Europe, 60000
cases are diagnosed yearly, compared to 500000 cases worldwide
(Chuaqui et al, 1997; Chan et al, 1998). Only a few biomarkers and
therapeutic gene targets are known to display alterations in
SCCHN. These include the commonly known markers for other
tumours, such as p53, p53Ab, p16, Rb, PTEN, EGFR, bcl2, p21, and
VEGF (Koch, 1999). Use of proliferation markers, such as Ki-67,
and proliferating cell nuclear antigen for diagnosis of SCCHN has
also been attempted, but they are not tumour-specific. To design
better strategies for targeting gene therapy, as well as for diagnosis
and prognosis, it is important not only to validate the existing
genes but also to discover novel genes for SCC (Sehgal et al, 1998).
This is also true for other types of tumours.
Since its invention in 1992, the DD technique has evolved into a
powerful method for elucidating changes in gene expression in
response to disease development and treatment, as well as studying
gene functions and cloning novel genes (Liang and Pardee, 1992;
Liang et al, 1992; Sun et al 1994; Lehar et al, 1996). Differential
display allows the mRNA profile of all genes expressed from two
different samples to be compared side by side, on the same gel,
making the simultaneous detection of both up- and downregulated
gene expression possible (Liang et al, 1992). This technique has
been widely used in studying up- or downregulated genes in many
tumour tissues, including prostate, thyroid (Musholt et al, 1997),
pancreatic (Ozaki et al, 1998), and breast cancers (Watson and
Fleming, 1994), colorectal and oesophageal carcinomas (Graber
et al, 1996; Chan et al, 1998), melanoma (Duncan et al, 1998), and
glioblastoma (Chuaqui et al, 1997; Sehgal et al, 1997). However, to
our knowledge, no study using this technique in primary SCCHN
tissues has been performed, although a few studies have reported
using mouse or tumour cell lines of SCCHN (Gorogh et al, 1997;
Patel et al, 1997; Gottschlich et al, 1999; Dong et al, 2001).
Here, we report the discovery of three genes differentially
expressed in SCCHN tissues. The most interesting gene is human
lung prostaglandin F synthase (hPGFS) that was increased in more
than 59% of larynx or hypopharynx SCC tumour tissues, compared
to matched surgical margins. The increased expression of hPGFS
was also detected in most of the tumour cell lines (55–80%)
derived from lung, colon, and head and neck cancer, but in a small
portion of tumour cell lines of leukaemia, breast, central nervous
system, renal, and ovary cancer. prostaglandin F synthase was not
detected in normal mucosal cell lines and melanoma cell lines.
Thus, the magnitude of increase in hPGFS expression seems
dependent on tumour types. Revised 27 October 2003; accepted 11 December 2003
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sMATERIALS AND METHODS
Cell culture and tissue specimen
SCCHN cell lines were obtained from the laboratories of Teresa
Whiteside, PhD (University of Pittsburgh, PA, USA) and Tom
Carey, PhD (University of Michigan, Albany, USA), and Normal
mucosal cell lines (NCM356, NCM425, and NCM 469) were
obtained from Incell Co, LLC (San Antonio, TX, USA). All cells
were grown in AIM-V medium supplemented with 10% foetal calf
serum, except for normal mucosal cell lines, which were grown in a
M13 medium (Incell Co., LLC). Normal mucosa, surgical margins,
and primary SCC tissues were obtained from 37 patients under-
going surgical resection of previously untreated SCCHN at the
University of Arkansas for Medical Sciences (UAMS). After
surgical removal, samples were immediately snap-frozen in a
liquid nitrogen container. All surgical margins used in this study
were determined to be pathologically negative. This protocol was
approved by the UAMS Institutional Review Board.
Differential display
For DD polymerase chain reaction (DD-PCR), normal mucosa,
negative surgical margins, and the matching tumour tissues were
homogenised with a bead-beater in TRIzol reagent (Life Technol-
ogies, Inc., Rockville, MD, USA), as described previously (Li et al,
1999), to extract total RNA. Total RNA (30mg) was treated with
10U of DNase I (MessageClean Kit, GenHunter Corp., Nashville,
TN, USA) for 30min at 371C to digest any DNA contaminants. The
flow chart for the procedure is outlined in Figure 1. Reverse
transcriptase (RT)–PCR was performed using the following
oligonucleotide primers: RT primer 50TTTTTTTTTTTN 30 (T11N;
N¼G,C,A) and arbitrary 10-mer primer (AP1-8) (GenHunter
Corp., Nashville, TN, USA). Total RNA (200ng) was reverse-
transcribed using 50U of Moloney murine leukaemia virus RT in
the presence of one RT primer (T11N) and 20mmol of deoxyr-
ibonucleoside triphosphate (dNTP) for 5min at 651C, followed by
60min at 371C. After heat inactivation of the RT at 951C for 5min
and subsequent cooling to 41C, 2ml of the cDNA samples were
added to 18ml of the PCR reaction mixture, containing 200nM of
one of the eight arbitrary 10-mer primers AP1-8 and T11N, 0.2mlo f
a
33P-dATP (2000CimM
 1; NEN Life Science Products, Inc.,
Boston, MA, USA), and 0.2ml of Taq DNA polymerase. The PCR
parameters during 40 cycles were 941C for 30s, 401C for 2min, and
721C for 30s. Finally, the samples were heated to 721C for 5min
and then cooled to 41C. The PCR products were analysed on 6%
DNA sequencing gels and exposed on an X-ray film. Bands of
interest were cut from the dried gels and boiled in a TE (tris-
EDTA) buffer to extract the DNA. The extracted DNA was further
amplified by PCR using the same set of primers. The amplified
DNA was subjected to agarose-gel electrophoresis, and the DNA
was purified from the gel with the use of a gel extraction kit
(Qiagen, Inc., Valencia, CA, USA). The recovered DNA samples
were subjected to sequencing with the matching T11N anchoring
primer, using a cycle sequence technique in the presence of a
radiolabeled terminator (USB Corp., Cleveland, OH, USA). The
recovered DNA was also used as template to make probes for
Northern blot analysis as described below.
Northern blot analysis
The technique used for Northern blot analysis was the same as that
described previously (Li et al, 1997). The extracted fragments that
were amplified by the PCR technique were used as probes for
Northern blot analysis. The probes were labelled with a
32P-dCTP
(3000CimM
 1, Amersham Pharmacia Biotech, Piscataway, NJ,
USA) using Strip-EZt PCR kit (Ambion, Inc., Austin, TX, USA,
USA). The RNA of SCCHN and normal mucosal cells were isolated
from our own cell culture by the methods described above.
Approximately 25mg of total RNA from tissues and 10mg from cell
lines were subjected to 1% agarose-formaldehyde gel electrophor-
esis at 60V for 3h. The RNA was transferred to a positively
charged nylon membrane (Boehringer Mannheim, Indianapolis,
IN, USA) and prehybridised and hybridised at 421C in a buffer
purchased from Ambion. Hybridisation of the same filters with a
probe for b-actin was used as an internal control for RNA loading,
and methylene blue staining was used to determine the relative
sizes of hybridised RNA (Li et al, 1997). The Northern blot results
were quantified by scanning the expression signal intensity with a
PhosphorImager analyser (Model 445 SI, Molecular Dynamics,
Sunnyvale, CA, USA).
Statistical analysis of hPGFS expression
The level of hPGFS expression between normal and tumour tissues
of larynx, hypopharynx, or overall sites was determined with
paired t-test. Statistical significance was defined as a Po0.05.
RESULTS
Determination of the appropriate controls for discovery of
novel tumour-related genes using DD-PCR and isolation of
SCCHN-related gene fragments
One of the most critical steps in the DD-PCR analysis was the
determination of a reliable control. Although this was a difficult
task with cultured cell lines, it was even more challenging when
primary tumour tissues were used. To determine the appropriate
control tissue to perform DD-PCR for isolation of the tumour-
specific gene from SCCHN, we tested normal mucosa, skin, and
negative surgical margins. Our primary analysis, using T11N
(N¼C,G,A) and an arbitrary 10-nucleotide primer, indicated that
the expression profile in skin tissue was totally different from the
profiles of normal mucosa, the tumour surgical margin, and the
tumour. On the other hand, both normal mucosa and negative
surgical margins demonstrated a similar gene expression profile
(Figure 2A and B), indicating either surgical margin or normal
mucosa can effectively serve as negative controls for DD-PCR
analysis. Thus, both of them were used as controls. Upon
comparison of the gene expression profile of tumour tissue with
those of surgical margins and normal mucosa, approximately 24
differentially expressed DNA fragments were identified by DD-
PCR (Figure 2C, Table 1). These DNA fragments were isolated
directly from the dried gel as summarised in Table 1.
Normal mucosa
or surgical margin
Tumour tissue
Isolation of total RNA
DD-PCR
with arbitray and anchor primer
Isolation of differentially
Expressed fragment
and reamplification
Cycle sequencing of DNA fragments
Blast search and excluding of duplicates
Northern blot confirmation
Figure 1 Outline of a modified differential display process for isolating
differentially expressed genes from SCCHN tissue.
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sequencing and Northern blot analysis
We had the option to exclude the false-positive fragments by
performing Northern blot analysis, first. Instead, we performed
sequence analysis of these fragments because the RNA samples
from primary tumour tissues were extremely hard to obtain, and
Northern blot analysis needed a relatively large amount of RNA for
each gene screening. We found duplicates for five out of 24
fragments, using BLAST search from the gene bank. Another time-
saving modification of this procedure was using the isolated DNA
fragments for direct sequence analysis instead of cloning prior to
sequencing. According to the sequence analysis, the majority of the
genes were unknown. The sizes of their cDNA were identified by
Northern blot analysis (Table 1), using the isolated DNA fragments
as probes. Among the 19 fragments, three were differentially
expressed in two separate pairs of tissues used for DD (Figure 3).
The rest either showed no change in gene expression or showed
change in one pair but not in the other pair of tissues (data not
shown). Among the three genes that were differentially expressed
on a uniform basis, two were downregulated and one upregulated.
The two downregulated genes in tumours were sFRP and
desmogelein 3 (DSG3); the upregulated gene was identical to the
sequence of hPGFS (Suzuki-Yamamoto et al, 1999) and KIAA0119
(Nagase et al, 1995), according to the BLAST search from gene
bank. As downregulation of secreted Frizzled-related protein
(sFRP) has been reported to be tumour-related (Finch et al,
1997), we did not further characterise this gene. Since the DSG3
cDNA is 7kb and it was difficult to obtain a high-quality Northern
blot result from the total RNA isolated from tumour tissues, we
plan to characterise it in the future using a different method. A
significant difference existed in the level of hPGFS expression
between tumour tissues from surgical margins, as determined by
Northern blot analysis (Figure 3).
Expression of hPGFS in the SCC primary tissues
To further demonstrate that hPGFS expression is elevated in
SCCHN tumours, we determined the level of hPGFS expression
using Northern blot analysis in 37 pairs of SCCHN and surgical
margin samples (Table 2). As demonstrated, the level of hPGFS
expression was increased in 15 out of 37 SCCHN tumour tissues.
Interestingly, the upregulation of hPGFS was detected in 10 out of
17 primary SCC tumours from larynx and hypopharynx (59%,
Po0.05), but in only a couple of oral SCC (Table 2). Increased
expression of hPGFS was independent of tumour stage.
NMT NMT NMT
Overexpressed
in tumour
in tumour
Downregulated
T M N
AB C
Figure 2 Identification of differentially expressed genes from SCCHN
tissue, normal mucosa (M), and negative surgical margin (N) with the use of
DD-PCR as described in the Materials and Methods section. (A, B)
Autoradiogram of DD-PCR using different 50 arbitrary 10-mer primer and
one 30 primer (T11N) (N¼C,G, A). (C) Autoradiogram to highlight the
gene fragments, which are either overexpressed or downregulated in
tumour tissue, cut out of the gel.
Table 1 Isolation of tumour-associated genes by DD-PCR and confirmation by Northern blot analysis
Name Primers Expression in tumour by DD-PCR Genes Accession number Size of mRNA Ratio of T/N by NB
A1-1 AP1,T11A Down sFRP NM003012 4.5kb 0.2
A4-1 AP4,T11A Down BENE NM005434 2.8kb NC
A4-5 AP5,T11A Down Unknown AC008149 1kb ND
A4-6 AP6,T11A Down DSG3 NM001944 7kb 0.3
A6-3 AP3,T11A Down Unknown AC161645 6kb NC
A6-2 AP2,T11A Down Unknown AC008513 ND NA
G4-1 AP4,T11G Down Unknown AC013391 ND NA
G4-2 AP2,T11G Down Unknown AC016738 ND NA
G4-5 AP5,T11G Down TGM3 AC031678 1kb NC
C2-1 AP1,T11C Down CILP AF035455 1kb NC
C3-1 AP1,T11C Down RTP D87953 4kb NC
C5-1 AP1,T11C Down EHHADH L07077 2.5kb IC
C6-1 AP1,T11C Down E2 X56832 7.6kb NA
A3-3 AP3,T11A Up P54NRB Y11298 2.6kb NA
A4-4 AP4,T11A Up hPGFS AB018580 1.2kb 16.1
G4-3 AP3,T11G Up Unknown AC087882 ND NA
G4-7 AP7,T11G Up PIGR P01833 4.3kb IC
G6-1 AP1,T11G Up Unknown AC357972 ND NA
C4-1 AP1,T11C Up Unknown AC139004 ND NA
NB¼Northern blot analysis; T/N¼average expression ratio in two tumours vs in two surgical margins; ND¼not determined; NC¼no change in expression; IC¼inconsistent
in expression; NA¼not available; DD-PCR¼differential display-polymerase chain reaction.
sFRP DSG3 hPGFS
NT NT NTNT NT NT
A1-1 A4-6 A4-4
Tublin
Figure 3 Northern blot analysis of three differentially expressed genes in
SCCHN tissues and the matching negative surgical margins. The purpose of
this study is to determine the expression of sFRP, DSG3, and hPGFS in two
pairs of tumours (T) and negative surgical margins (N). The gene probes
were isolated from differential display dried gels, and subjected to sequence
analysis. The names of gene fragments were defined by BLAST search from
the gene bank at the National Cancer Institute (NCI). Actin was used as an
internal control.
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sExpression of epidermal growth factor receptor (EGFR) in
the primary tissues derived from surgical margins and
tumours
To determine whether the increased level of hPGFS expression
correlates to the expression of a well-known tumour marker and
drug target, EGFR. The same Northern blot membranes used for
analysing hPGFS expression were hybridised with the EGFR probe.
As shown in Table 2, 12 out of 37 tumour samples demonstrated
more than a 1.5-fold increase in the level of EGFR expression.
There is no direct correlation between EGFR and hPGFS
expression. However, a high frequency (46.7%) of elevated
expression of EGFR was found in the tumours in which increased
expression of hPGFS was also found; a low frequency (22.7%) of
elevated EGFR expression was found in the tumours in which
hPGFS expression was not increased or decreased (Table 3).
Expression of hPGFS was detected primarily in tumour cell
lines from respiratory and digestive organs
To verify that increased expression of hPGFS in primary SCCHN
tumours was at least partially due to the increase in tumour-cell
expression, we analysed hPGFS expression in five SCCHN cell
lines, and 59 tumour cell lines derived from tumours from other
organs, including breast, prostate, renal, colon, lung, blood, central
nervous system, ovary, and skin. Three normal mucosal cell lines,
NCM356, NCM425, and NCM460, were used to compare the
relevant level of hPGFS expression. The expression of hPGFS in
tumour cell lines was defined as more than a two-fold increase
over the level of the control cell line NCM425. As demonstrated by
Northern blot results, in Figure 4 and Table 3, the level of hPGFS
was increased 8.6- to 74.5-fold in four out of five cell lines from
SCCHN; 2.1- to 105-fold in five out of seven cell lines from colons.
Thus, the increased expression of hPGFS detected in tumours
(Figure 3, Table 2) was at least partially due to its upregulation in
tumour cells (Figure 4, Table 3). Interestingly, hPGFS was not
detected in melanoma (zero out of nine) cell lines, but was detected
in a small proportion of tumour cell lines derived from breast,
central nervous system, ovarian, leukaemia, and renal cancer
(Table 3). The magnitude of increase in hPGFS expression in these
tumour cell lines was also low. However, hPGFS was significantly
increased in tumour cell lines derived from colon cancer, Non-
small-cell (NSC) lung cancer, head and neck cancer. Up to a 500-
fold increase of hPGFS expression was detected (Table 3),
suggesting that the high level of hPGFS expression was associated
with tumour types.
DISCUSSION
Using a modified DD-PCR technique, in combination with analysis
of DNA sequence and gene expression by bioinformatics and
Table 2 hPGFS and EGFR expression in tumours and surgical margins
Samples T N M Tissue origion hPGFS (T/N) EGFR (T/N)
X19-2 1 n/a 0 Larynx/glottis 16 2.9
X22-9 4 2b 0 Oral cavity/FOM-ant 15 5.4
X19-11 2 n/a 0 Nasal SCC 10 No diff
X23-1 1 n/a 0 Oral cavity/lateral tongue 10 No diff
X13-14 3 0 0 Larynx/glottis 9.6 1.5
X26-3 8.4 3.3
X16-3 4 2c 0 Larynx/glottis 7.3 1.6
X14-4 4 0 0 Hypo/piri 7 No diff
X24-9 2 0 0 Larynx/supraglottis 6 LE
X22-8 2 1 0 Hypopharynx/pyriform 4 2.7
X19-14 2 n/a 0 Hypopharynx/pyriform 3.5 No diff
X14-2 4b 0 0 Maxillary sinus 2.7 No diff
X19-1 2 n/a 0 Larynx/supraglottis 2.6 1.9
X19-7 4 2c 0 Larynx/supraglottis 2.2 No diff
X23-3 3 3 0 Larynx/glottis 2 No diff
X14-5 4 2b 0 Oral cavity/palette No diff No diff
X16-1 3 n/a 0 Oral pharynx/bot No diff No diff
X19-10 4 2b 0 Oral cavity/FOM No diff 0.4
X19-12 n/a 1 0 Larynx/glottis No diff 1.7
X19-13 1 n/a 0 Larynx/glottis No diff No diff
X19-15 1 0 0 Oral cavity/tongue No diff No diff
X19-3 2 0 0 Oral cavity/FOM No diff 1.7
X19-4 3 0 0 Larynx/glottis No diff 2.3
X19-9 4 n/a 0 Oral cavity/palette No diff No diff
x22-4 4 3 n/a No diff No diff
X22-6 3 2b 0 Oral cavity/FOM No diff No diff
X23-10 2 0 0 Oral cavity/lateral tongue No diff No diff
X23-2 3 1 0 Oral pharynx/tonsil No diff No diff
X23-4 2 1 0 Oral cavity No diff 2.5
X23-5 2 3 0 Oral cavity/tongue No diff No diff
X24-3 n/a n/a n/a Oral cavity No diff No diff
X24-5 2 n/a n/a Oral cavity No diff No diff
X24-6 2 n/a 0 Paranasalsinus/max No diff No diff
X24-7 3 0 0 Hypopharynx/pyriform No diff No diff
X26-5 No diff No diff
X24-2 n/a 2b 0 Larynx/glottis 0.5 No diff
X26-4 n/a n/a n/a n/a 0.1 4.4
T/N, the ratio of gene expression in the tumour vs in the matched surgical margin.
Linkage of hPGFS expression
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One revelation was the downregulation of an apoptosis candidate
gene, sFRP, and a tumorigenesis suppressor gene, DSG3, in SCCHN
that are also found by other investigators in other tumour tissues
(Finch et al, 1997; Zhou et al, 1998), demonstrating that different
tumours may share a common molecular mechanism in tumor-
igenesis. The other was discovering the linkage of increased
expression of hPGFS to multiple tumours. The increased expres-
sion of hPGFS may link to tumorigenesis and maybe able to serve
as a potential molecular marker and drug target as supported by
three lines of evidence discussed below.
The first line of evidence came from the biochemical function of
hPGFS. hPGFS was cloned from a human lung cDNA library with
the use of bovine PGF in 1999. The sequence analysis indicated
that this cDNA matched KIAA0119, cloned from the human
immature myeloid cell line KG-1 in 1995 (Nagase et al, 1995).
Although the biological function of KIAA0119 is not clear, its
biochemical function might serve as a steroid dehydrogenase. The
deduced amino-acid sequence was identical to that of AKR1C3,
except for two amino acids (Khanna et al, 1995). The enzymatic
study demonstrated that the natural substrates of hPGFS were
PGD2 and PGF2, but not steroid hormones such as dihydrotes-
tosterone, catalysed by AKR1C3 (Suzuki-Yamamoto et al, 1999). It
has been known that cyclooxygenase 2 (Cox2) is overexpressed in
head and neck tumour tissues, induces tumorigenesis, and
modulates the production of PGD2 (Kawamori et al, 1998). Thus,
these two enzymes are in the same biochemical pathway and they
may coordinate with each other in promoting tumorigenesis by
Table 3 hPGFS expression in tumour cell lines
Tissue origion Cell lines Level of increase Cell lines Tumours Level of increase
Normal mucosa NCM356 0.8 Melanoma RPMI7951 1.4
NCM425 1.0 Malme3M 1
NCM460 1.5 LoxIMVI 0.6
UACC62 0.4
SCCHN UMSCC38 74.5 UACC257 0.2
PCI52 67.2 SK-MEL5 0.2
PCI1 8.6 SK-MEL28 0.2
UMSCC2 9.5 SK-MEL-2 0.6
M14 0.2
Colon cancer COLO205 105 Leukemia K562 6.6
HCC2998 32.8 CCrf-Cem 1.4
HT29 5.9 MOLT4 0.8
KM126 2.1 SR 0.4
SW620 6.2 HL60 0.4
HCT15 0.8
HCT116 1.7
Non-small-cell lung cancer A549 500.4 Breast cancer MCF7 4.6
NCI-H226 123.4 MDA-MB231 0.4
NCI-H460 66.7 MDA-MB469 0.4
NCI-H23 9.8 NCI/ADR-RES 0.4
EKVX 8.4 HS578T 0.4
HOP-92 1.0 BT549 1
NCI-H322m 0.8 T47 D 0.4
NCI-H522 0.6
HOP-62 0.6
Renal cancer A498 79.4 CNS cacner SF539 6.0
TK10 6.8 SF295 3.2
CAKI-1 3.4 U251 1.4
786-0 1.8 SNB75 0.6
RXF393 1.6 SNB19 0.4
ACHN 0.8 SF268 0.4
UO31 0.6
SN12C 0.2
Ovarian cancer SK-OV3 15.8
Ovcar5 1.8
IGROV1 0.8
OVCAR14 0.6
OVCAR8 0.4
OVCAR3 0.4
hPGFS expression in different cell lines was normalised from the expression of NCM425, a normal colon mucosa cell line.
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Figure 4 Northern blot analysis of gene expression in cell lines derived
from normal mucosa and tumours of SCCHN and colon. NCM356,
NCM425 and NCM460 are normal mucosal cell lines. COLO205,
HCC2998, HT29, KM126, SW620, HCT15 and HCT116 are colon
tumour cell lines. PCI52 and PCI1 are tumour cell lines of SCCHN. (A)
Increased expression of hPGFS in SCCHN tumour cell lines. (B) Elevated
expression of hPGFS in colon tumour cell lines. Actin was used as an
internal control.
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favour tumorigenesis (Subbaramaiah et al, 1997) through im-
munosuppression and increasing neovascularisation (Nugent et al,
1996). However, the exact roles of PGFS and PGD2 in tumorigen-
esis have not been studied yet. The other PGD downstream
molecule, PGE, is known to suppress the immune system, which
may promote tumorigenesis. We speculate this may also be the
case for PGF2.
The second line of evidence to support increased expression of
hPGFS is a potential tumour marker and a drug target that came
from the wide expression of this gene in tumour cell lines from
many different tumour types. Interestingly, the expression of
hPGFS was preferentially increased in tumour cell lines derived
from tumours located in respiratory and digestive organs. Up to a
500-fold increase in hPGFS expression was found in the tumour
cell lines derived from the colon, lung, head and neck (Table 3). A
higher frequency of elevated hPGFS expression in SCCHN
tumours, compared to the frequency of increased EGFR
expression, was found in this study (Table 2). However, the
expression of hPGFS in tumour cell lines of melanoma, central
nervous system, leukaemia, breast, renal, and ovarian cancer was
either not detected or only modestly increased in a small portion of
cell lines examined. Thus, hPGFS may also be a potential drug
target for some of the tumours because the huge differential
expression between some types of the tumours, in which a high
level of expression occurs.
The third line of evidence to support the notion that increased
hPGFS expression can be used as a potential molecular marker and
a drug target is that hPGFS increased in a large number of primary
tumour tissues. As shown in Table 2, hPGFS was increased in 10
out of 17 (59% Po0.05) larynx and hypopharynx SCC compared
with negative surgical margins tissues. The overall frequency of
elevated hPGFS expression in SCCHN tumours (40.5%) exceeds
the frequency of EGFR (32.4%), a well-known molecular marker
and drug target for multiple types of tumours. Moreover, these two
markers may complement each other to make a better diagnosis
than use of a single marker because the elevated expression of
these two genes does not occur in the same tumour sample
(Table 2). Combining hPGFS with EGFR and other tumour
markers will certainly increase the accuracy of molecular diagnosis
for specific type of tumours.
The magnitude of increased expression of hPGFS varied
among different tumour tissues, despite the use of a consistent
sampling procedure. One possibility is the heterogeneity in
the tumour tissues from different patients. Microscopic laser
capture of tumour-specific cells could avoid this problem,
but it was impossible to get enough RNA from each of the
37 tumour tissues for Northern blot analysis. Although the PCR-
based quantitation requires a less amount of RNA, the high
homology of hPGFS with several other genes such as AKR1C3 (two
amino acids difference) hindered this approach. The tissue
heterogeneity-caused variation in hPGFS expression can be better
examined when an hPGFS-specific antibody becomes commer-
cially available.
In conclusion, this is the first demonstration that hPGFS is
differentially expressed mainly in SCC of larynx and hypopharynx,
as well as tumour cell lines derived from lung and colon cancer.
Therefore, it may be a potential therapeutic target for these
cancers.
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